OTC:NEVPF

NeuroVive's KL1333 Receives FDA Orphan Drug Designation for Treatment of Mitochondrial Diseases

LUND, Sweden, April 18, 2018 /PRNewswire/ --NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF), the mitochondrial medicine company, today announced that it has been granted Orphan Drug Designation by the United States FDA Office of Orphan Products Development for its project KL133...

2018-04-18 15:57 658

NeuroVive's Partner Yungjin Pharm Completes KL1333 Phase I Study Recruitment

LUND, Sweden, April 17, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB  (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today announced that the last visit of the last healthy volunteer in the clinical phase I single ascending dose ...

2018-04-17 15:03 645

Notice of Extraordinary General Meeting of NeuroVive Pharmaceutical AB (publ)

LUND, Sweden, Feb. 15, 2018 /PRNewswire/ -- The shareholders of NeuroVive Pharmaceutical AB (publ), 556595-6538, are hereby convened to the Extraordinary General Meeting, held at2 pm on Thursday 22 March 2018 at Medicon Village, Scheelevagen 2, in Lund, Sweden. Entitlement to participate and no...

2018-02-15 16:35 841

NeuroVive Decides on a Rights Issue for Continued Drug Development

LUND, Sweden, Feb. 15, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (publ) (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announces that the Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or "the Company") on15 February 2018 resolved, subject to approval by the Extraordinary Gen...

2018-02-15 16:18 841

NeuroVive Reports Breakthrough in Mitochondrial Myopathy Project

LUND, Sweden, Jan. 29, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced a breakthrough in the company's project NVP025 for developing treatment of mitochondrial myopathy. In an experimental study carried out in collaboration with researchers at...

2018-01-29 21:05 727

NeuroVive to Present at the 10th Annual Biotech Showcase Conference

LUND, Sweden, Jan. 3, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), today announced that the company is scheduled to present the 10th Annual Biotech Showcase Conference, held8-10 January 2018 in San Francisco, USA. The presentation will highlight the com...

2018-01-03 16:10 950

NeuroVive Reports Promising Progress in its Clinical Project for Genetic Mitochondrial Diseases, KL1333

LUND, Sweden, Dec. 11, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm today announced that the phase I clinical study in Korea within the companies' joint project KL1333, an investigational treatment for genetic mitochondrial disorders, inc...

2017-12-11 18:56 1479

Amended Number of Shares and Votes in NeuroVive Pharmaceutical AB (publ)

LUND, Sweden, Nov. 30, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced an increase of the number of shares and votes in NeuroVive of 1,760,000 as a result of a directed share issue in NeuroVive Pharmaceuti...

2017-11-30 19:51 815

NeuroVive's Genetic Mitochondrial Disease Program NVP015 Reaches Significant Milestone

LUND, Sweden, Nov. 30, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that molecules in its NVP015 program have demonstrated positive effects in experimental models of genetic mitochondrial disease and th...

2017-11-30 16:26 775

NeuroVive Presents TBI Clinical Study Results at Nordic Neurotrauma Conference

LUND, Sweden, Nov. 15, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company will present data from its clinical phase IIa study on traumatic brain injury (TBI), Copenhagen Head Injury Ciclosporin Study (CHIC), at the Nordic Neurot...

2017-11-15 16:48 724

NeuroVive Board Chair Resigns, New Chair Elected

LUND, Sweden, Nov. 7, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announces thatGregory Batcheller resigned as Chair of the NeuroVive Pharmaceutical AB Board effective midnightNovember 6, 2017. He had served as the Executive Chair of NeuroVive for the p...

2017-11-07 15:55 707

NeuroVive Conducts a Directed New Share Issue of SEK 5.3 Million

LUND, Sweden, Nov. 3, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), a leading company in mitochondrial medicine, announced today that the company is conducting a directed new issue of shares, which is expected to add close toSEK 5.3 million to NeuroVive...

2017-11-03 16:33 834

NeuroVive Signs Collaboration Agreement With University of Florida for TBI Biomarker Development

LUND, Sweden, Oct. 31, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company has signed a collaboration agreement withKevin K.W. Wang, Ph.D., of the University of Florida to conduct biomarker research for NeuroVive's traumatic brai...

2017-10-31 16:32 693

NeuroVive and Lund University Collaboration Receives Grant for Liver Cancer Research

LUND, Sweden, Oct. 18, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that NeuroVive andRamin Massoumi at Lund University have been granted 2.5 MSEK from the Swedish Foundation for Strategic Research (SFF...

2017-10-18 15:05 1030

NeuroVive's Collaborator, the Children's Hospital of Philadelphia Awarded NIH Grant to Study NVP015 Against Chemical Threats

LUND, Sweden, Oct. 6, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (NASDAQ Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that its research collaboration partner the Children's Hospital ofPhiladelphia (CHOP) has received a two-year grant, #1R21NS103826-01f ...

2017-10-06 05:44 908

NeuroVive Receives Research Grant From Vinnova for Development of the NVP015 Genetic Mitochondrial Disease Project

LUND, Sweden, June 1, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company receives close to 1 million SEK in a research grant from Swedish innovation agency, Vinnova, for developing a new treatment for genetic mitochondrial diseas...

2017-06-01 19:52 2457

NeuroVive Pharmaceutical AB Interim Report January - March 2017

STOCKHOLM, May 18, 2017 /PRNewswire/ -- Broadened project portfolio Business operations Significant events January-March 2017 * Strong inhibitory effects demonstrated in human hepatocellular carcinoma cells and in an experimental model of liver cancer with the Company's new generation of s...

2017-05-18 15:18 1704

NeuroVive in-licenses a Genetic Mitochondrial Disease Clinical Stage Project From Yungjin Pharm

LUND, Sweden and SEOUL, South Korea, May 2, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today jointly announced that they have entered into a global licensing agreement on Yungjin P...

2017-05-02 11:51 1727

NeuroVive Presents Preclinical Findings of NV556 in NASH Showing Confirmatory Anti-fibrotic Effects

LUND, Sweden, April 20, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) ("NeuroVive")today announced positive preclinical results demonstrating anti-fibrotic effects with NV556, the company's preclinical compound for non-alcoholic steatohepatitis (NASH), in ...

2017-04-20 15:05 1762
12